🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "major milestone" in the battle against drug-resistant strains of the pathogen, according to researchers.

A Worldwide Health Concern

Gonorrhoea infections are increasing worldwide, with data suggesting over 82 million instances each year. Notably increased rates are seen in Africa and nations within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary development in the context of increasing worldwide cases, escalating drug resistance and the extremely scarce therapeutic options presently on offer.”

Public health authorities are deeply concerned about the surge in antibiotic-resistant strains. The WHO has designated it as a "priority pathogen". Ongoing monitoring showed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Drugs Gain Approval

Zoliflodacin, also known as a brand name, was approved by the US FDA in recent days for combating gonorrhoea. This infection can lead to serious health problems, including infertility. Experts believe that targeted use of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This medication, which is also used to treat UTIs, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

This new treatment emerged from a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to see it through.

“This milestone marks a major breakthrough in the treatment of highly resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Clinical Trial Results and Global Access

Based on results detailed in a prominent scientific publication, zoliflodacin eradicated over nine in ten of genital gonorrhoea infections. This establishes an comparable level with the current standard treatment, which uses an injection and a pill. The research enrolled over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the ability to make available and distribute the drug in a wide range of regions with limited resources.

Doctors treating patients have shared hope. The availability of a single-dose, oral treatment like this is hailed as a "critical tool" for managing the epidemic. This is considered vital to reduce the burden of the disease for people and to stop the proliferation of untreatable gonorrhoea around the world.